HelixBind, Inc.
HelixBind is developing an innovative diagnostic platform to revolutionize care for bloodstream infections. Its proprietary platform provides faster, more accurate, and more informative microbiology results, assisting clinicians in precisely identifying invasive infections and developing personalized antimicrobial interventions for infected patients. The company aims to improve outcomes, reduce the spread of antimicrobial resistance, and save lives through cutting-edge technology and rapid diagnostics.
Industries
Nr. of Employees
small (1-50)
HelixBind, Inc.
1300 Massachusetts Avenue, Unit 103, Boxborough, MA 01719
Patents
Methods and compositions for the diagnosis of sepsis using gamma peptide nucleic acids
US-11091814-B2
View Details
Methods and compositions for the diagnosis of sepsis using gamma peptide nucleic acids
US-11091814-B2
View DetailsProducts
Benchtop rapid diagnostic instrument and disposable sample cassette (sample-to-answer)
An automated, integrated diagnostic system comprising a small benchtop instrument and single-use disposable fluidic cassettes that process a blood specimen and deliver species-level pathogen identification and resistance marker information within a few hours.
Benchtop rapid diagnostic instrument and disposable sample cassette (sample-to-answer)
An automated, integrated diagnostic system comprising a small benchtop instrument and single-use disposable fluidic cassettes that process a blood specimen and deliver species-level pathogen identification and resistance marker information within a few hours.
Services
On-site deployment of benchtop diagnostic instruments and consumable cassettes, including integration with hospital LIS and user workflow automation.
Collaborative studies to evaluate assay performance for identifying bloodstream infections and associated clinical utility.
On-site deployment of benchtop diagnostic instruments and consumable cassettes, including integration with hospital LIS and user workflow automation.
Collaborative studies to evaluate assay performance for identifying bloodstream infections and associated clinical utility.
Expertise Areas
- Direct-from-blood molecular diagnostics
- Assay and sample-preparation development
- Integrated microfluidic device engineering
- Automated sample-to-answer platform engineering
Key Technologies
- Direct-from-blood molecular detection
- Artificial/engineered nucleic acid chemistries
- Integrated microfluidics and disposable cassettes
- Automated sample-to-answer instrumentation
News & Updates
HelixBind was recognized as a Phase 3 winner of the LymeX Diagnostics Prize by HHS and the Steven & Alexandra Cohen Foundation in January 2025.
Funding to support validation and commercialization of the company's RaPID diagnostic platform.
Patent covering devices for the direct detection and identification of microorganisms in complex matrices such as blood.
A study demonstrating the potential of HelixBind’s assay to accurately identify bloodstream infections associated with sepsis.
HelixBind was recognized as a Phase 2 winner of the LymeX Diagnostics Prize by HHS and the Steven & Alexandra Cohen Foundation in February 2024.
HelixBind was awarded a $3 million NIH grant in June 2021 to support testing of its diagnostic platform for invasive infections.
HelixBind was recognized as a Phase 3 winner of the LymeX Diagnostics Prize by HHS and the Steven & Alexandra Cohen Foundation in January 2025.
Funding to support validation and commercialization of the company's RaPID diagnostic platform.
Patent covering devices for the direct detection and identification of microorganisms in complex matrices such as blood.
A study demonstrating the potential of HelixBind’s assay to accurately identify bloodstream infections associated with sepsis.
HelixBind was recognized as a Phase 2 winner of the LymeX Diagnostics Prize by HHS and the Steven & Alexandra Cohen Foundation in February 2024.
HelixBind was awarded a $3 million NIH grant in June 2021 to support testing of its diagnostic platform for invasive infections.